FDA PMA Approval: The Class III Guide (2026)

Premarket Approval — PMA — is the FDA's most demanding device route and the one behind the highest-stakes products: implantable defibrillators, novel stents, artificial heart valves, breakthrough diagnostics. If 510(k) asks "is it equivalent to something on the market," PMA asks "prove it is safe and effective" — with real evidence. This guide covers when PMA is required, what the evidence bar looks like, the original PMA process step by step, how supplements work after approval, realistic timelines and costs, and the two escape routes (HDE and Breakthrough designation) that change the math.

This is planning intelligence, not legal or regulatory advice. It summarizes FDA requirements, guidance, and industry reporting as of September 2026. Submission requirements, user fees, and review timelines change — confirm every detail with qualified regulatory counsel before committing a calendar or a budget. Nothing here guarantees approval.

When PMA is required — and the terminology that matters

PMA is the route for Class III devices: those that support or sustain human life, are of substantial importance in preventing impairment of health, or present a potential unreasonable risk of illness or injury. Most Class III devices cannot use 510(k) because no adequate predicate exists at that risk level. Two terminology points carry legal weight. The FDA approves PMAs and clears 510(k)s — mixing them up in labeling or promotion is a compliance problem. And "approval" reflects the evidence standard: reasonable assurance of safety and effectiveness, demonstrated with valid scientific evidence, which for most original PMAs means clinical data.

The evidence bar: what "reasonable assurance" looks like

A PMA stands or falls on its clinical evidence package. The typical original PMA includes bench and animal testing, a clinical study designed around agreed endpoints, manufacturing and quality-system documentation, and labeling. The critical move happens before the study: engaging the FDA early — through the Q-Submission program and, where available, an Investigational Device Exemption (IDE) — to align on study design, endpoints, and statistical plans. A trial that answers the wrong question is the most expensive mistake in the PMA world.

• Align endpoints and study design with the FDA before enrolling — IDE and Q-Sub meetings are where PMAs are won
• Build the quality system to QMSR from day one: the regulation took effect in February 2026 and the FDA expects ISO 13485-aligned documentation
• Plan manufacturing scale-up early — pre-approval inspection of facilities is a normal part of the process
• Document software and cybersecurity to the FDA's risk-based expectations, including SBOM and vulnerability plans for connected devices
• Design the trial for the labeling you want — the approved indications follow the studied population

Step by step: the original PMA

• Classify and confirm: verify the device is Class III and that no 510(k) or De Novo route fits — the classification decision gates everything
• Pre-submission engagement: Q-Sub meetings to align on the clinical plan, endpoints, and evidence expectations
• IDE (if needed): FDA authorization to run the US clinical study
• Run the study: clinical data generation against the agreed endpoints, with design controls and data integrity throughout
• Assemble the PMA: clinical, nonclinical, manufacturing, software, and labeling modules — in eSTAR-compatible electronic form
• FDA review: filing review, substantive review, possible advisory panel for novel devices, manufacturing inspection
• Decision: approval, approvable letter with conditions, or not-approvable — each with a defined response path

Advisory panels: when outsiders get a vote

For novel or first-of-a-kind PMAs, the FDA may convene an advisory panel of outside experts to review the data and vote on approvability. Panels do not make the decision — the FDA does — but a negative panel vote is very hard to overcome. Panel preparation is its own discipline: the sponsor presents, the FDA presents its own analysis, and the panel questions both. Companies that rehearse against the FDA's likely criticisms, rather than their own marketing story, do materially better.

After approval: supplements, not silence

Approval is not the end of FDA interaction — it is the start of lifecycle management. Changes to an approved device, its manufacturing, or its labeling require a PMA supplement, with the supplement type matched to the change's risk: minor changes may use streamlined reporting, while design or indication changes need full review. Annual reports keep the FDA informed of ongoing experience. Planning the supplement strategy before approval — what the next two product generations will change — is how mature PMA holders avoid re-learning the process under time pressure.

Timelines and costs: the honest numbers

The MDUFA V performance goal for an original PMA decision is 180 FDA days — again, FDA days, excluding time the clock spends with the sponsor. In practice, the full journey from clinical study design to approval runs in years, not months: the trial itself dominates the timeline. PMA user fees are an order of magnitude above 510(k) fees, with small-business reductions available — this guide states no dollar figures because the schedule changes every fiscal year. The dominant cost is almost always the clinical program, not the fee or the submission.

Two routes that change the math: HDE and Breakthrough

The Humanitarian Device Exemption (HDE) serves devices for conditions affecting fewer than 8,000 people in the US per year: the evidence standard is safety plus probable benefit rather than full effectiveness, which can dramatically shorten the clinical program. The Breakthrough Devices Program is not a separate marketing route but a designation that buys intensive FDA interaction and review prioritization for devices addressing life-threatening or irreversibly debilitating conditions — most breakthrough-designated devices still go through PMA or 510(k), but with a faster, more predictable review.

For the structured pathway view — regulator, conformity route, and document logic — see the GHMAP regulatory pathways/united-states/class-ii page for the FDA route and the EU Class III regulatory pathway page for the EU's highest-risk route on ghmap.io.

Mistakes that kill PMAs

• Running the pivotal trial before aligning endpoints with the FDA
• Treating the quality system as a submission-time paperwork exercise instead of a QMSR-aligned process from day one
• Underestimating the manufacturing inspection — facilities that are not inspection-ready delay approval
• Walking into an advisory panel with a marketing presentation instead of answers to the FDA's criticisms
• Forgetting the supplement strategy — first-generation approval that blocks the second generation's design changes

PMA is the longest, most expensive FDA route — and for true Class III innovation, the only one. The winners decide the evidence strategy with the FDA before the first patient is enrolled, and treat approval as the start of lifecycle management rather than the finish line.